Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Role of Adjuvant Radiotherapy in Gastric Cancer

  • Jeong Il Yu (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2022.10.13
  • Accepted : 2022.11.15
  • Published : 2023.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Although continuous improvement in the treatment outcome of localized gastric cancer has been achieved through early screening, diagnosis, and treatment and the active application of surgery and adjuvant chemotherapy, the necessity of adjuvant radiotherapy (RT) remains controversial. In this review, based on the results of two recently published randomized phase III studies (Adjuvant Chemoradiation Therapy In Stomach Cancer 2 and ChemoRadiotherapy after Induction chemoTherapy of Cancer in the Stomach) and a meta-analysis of six randomized trials including these two studies, the role of adjuvant RT in gastric cancer was evaluated and discussed, especially in patients who underwent curative gastrectomy with D2 lymphadenectomy. This article also reported the possible indications for adjuvant RT in the current clinical situation and in future research to enable patientspecific treatments according to the risk of recurrence.

Keywords

Acknowledgement

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education (NRF-2022R1C1C1005415).

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.  https://doi.org/10.3322/caac.21660
  2. Jung KW, Won YJ, Kang MJ, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2022. Cancer Res Treat 2022;54:345-351.  https://doi.org/10.4143/crt.2022.179
  3. Song Y, Liu X, Cheng W, Li H, Zhang D. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci Rep 2022;12:11542. 
  4. Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea Central Cancer Registry data (1999-2019). J Gastric Cancer 2022;22:160-168.  https://doi.org/10.5230/jgc.2022.22.e21
  5. Heer EV, Harper AS, Sung H, Jemal A, Fidler-Benaoudia MM. Emerging cancer incidence trends in Canada: the growing burden of young adult cancers. Cancer 2020;126:4553-4562.  https://doi.org/10.1002/cncr.33050
  6. Kim B, Cho SJ. Endoscopic screening and surveillance for gastric cancer. Gastrointest Endosc Clin N Am 2021;31:489-501.  https://doi.org/10.1016/j.giec.2021.03.004
  7. Eom BW, Jung KW, Won YJ, Kim YW. Trends and outcomes of non-compliance with treatment for gastric cancer in Korea over the 16 years from 1999 to 2015. J Gastric Cancer 2019;19:92-101.  https://doi.org/10.5230/jgc.2019.19.e5
  8. Lawson JD, Sicklick JK, Fanta PT. Gastric cancer. Curr Probl Cancer 2011;35:97-127.  https://doi.org/10.1016/j.currproblcancer.2011.03.001
  9. Wang SB, Qi WX, Chen JY, Xu C, Kirova YM, Cao WG, et al. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy. Radiat Oncol 2019;14:128. 
  10. Lehnert T, Erlandson RA, Decosse JJ. Lymph and blood capillaries of the human gastric mucosa. A morphologic basis for metastasis in early gastric carcinoma. Gastroenterology 1985;89:939-950.  https://doi.org/10.1016/0016-5085(85)90192-1
  11. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021;32:368-374.  https://doi.org/10.1016/j.annonc.2020.11.017
  12. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616-628. https://doi.org/10.1016/S1470-2045(18)30132-3
  13. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017;24:2252-2258.  https://doi.org/10.1245/s10434-017-5830-6
  14. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.  https://doi.org/10.1200/JCO.2011.39.1953
  15. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.  https://doi.org/10.1056/NEJMoa010187
  16. Lee J, Kim WC, Yoon WS, Rim CH. Implications of radiotherapy utilization in Korea from 2010 to 2019. J Korean Med Sci 2021;36:e117. 
  17. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329. 
  18. Nogueira LM, Jemal A, Yabroff KR, Efstathiou JA. Assessment of proton beam therapy use among patients with newly diagnosed cancer in the US, 2004-2018. JAMA Netw Open 2022;5:e229025. 
  19. Collings EW, Lu L, Gupta N, Sumption MD. Accelerators, gantries, magnets and imaging systems for particle beam therapy: recent status and prospects for improvement. Front Oncol 2022;11:737837. 
  20. Mondlane G, Gubanski M, Lind PA, Ureba A, Siegbahn A. Comparison of gastric-cancer radiotherapy performed with volumetric modulated arc therapy or single-field uniform-dose proton therapy. Acta Oncol 2017;56:832-838.  https://doi.org/10.1080/0284186X.2017.1297536
  21. Yamaguchi H, Honda M, Hamada K, Kobayashi H, Todate Y, Seto I, et al. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol 2020;50:903-908.  https://doi.org/10.1093/jjco/hyaa052
  22. Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol 2012;9:688-699.  https://doi.org/10.1038/nrclinonc.2012.194
  23. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.  https://doi.org/10.1016/0360-3016(82)90377-7
  24. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin 2021;71:264-279.  https://doi.org/10.3322/caac.21657
  25. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436.  https://doi.org/10.1200/JCO.2009.26.9654
  26. Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol 2012;104:367-373.  https://doi.org/10.1016/j.radonc.2012.08.017
  27. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014;101:23-31.  https://doi.org/10.1002/bjs.9345
  28. Yu JI, Lim DH, Ahn YC, Lee J, Kang WK, Park SH, et al. Effects of adjuvant radiotherapy on completely resected gastric cancer: a radiation oncologist's view of the ARTIST randomized phase III trial. Radiother Oncol 2015;117:171-177.
  29. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.  https://doi.org/10.1056/NEJMoa072252
  30. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15- year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449.  https://doi.org/10.1016/S1470-2045(10)70070-X
  31. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.  https://doi.org/10.1016/S0140-6736(11)61873-4
  32. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOGdirected intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333.  https://doi.org/10.1200/JCO.2011.36.7136
  33. Conrad T, MacLellan S, Kassam Z, Mackay H, Khalili I, Sykes J, et al. Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. Gastric Cancer 2016;19:887-893.  https://doi.org/10.1007/s10120-015-0534-8
  34. Pachaury A, Chaudhari V, Batra S, Ramaswamy A, Ostwal V, Engineer R, et al. Pathological N3 stage (pN3/ ypN3) gastric cancer: outcomes, prognostic factors and pattern of recurrences after curative treatment. Ann Surg Oncol 2022;29:229-239.  https://doi.org/10.1245/s10434-021-10405-3
  35. Nam H, Lim DH, Kim S, Kang WK, Sohn TS, Noh JH, et al. A new suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer. Int J Radiat Oncol Biol Phys 2008;71:448-455.  https://doi.org/10.1016/j.ijrobp.2007.09.055
  36. Eom SS, Choi W, Eom BW, Park SH, Kim SJ, Kim YI, et al. A comprehensive and comparative review of global gastric cancer treatment guidelines. J Gastric Cancer 2022;22:3-23.  https://doi.org/10.5230/jgc.2022.22.e10
  37. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48.  https://doi.org/10.5230/jgc.2019.19.e8
  38. Degiuli M, Reddavid R, Tomatis M, Ponti A, Morino M, Sasako M, et al. D2 dissection improves diseasespecific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer 2021;150:10-22.  https://doi.org/10.1016/j.ejca.2021.03.031
  39. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21.  https://doi.org/10.1007/s10120-020-01042-y
  40. Mogal H, Fields R, Maithel SK, Votanopoulos K. In patients with localized and resectable gastric cancer, what is the optimal extent of lymph node dissection-D1 versus D2 versus D3? Ann Surg Oncol 2019;26:2912-2932.  https://doi.org/10.1245/s10434-019-07417-5
  41. de Steur WO, van Amelsfoort RM, Hartgrink HH, Putter H, Meershoek-Klein Kranenbarg E, van Grieken NCT, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol 2021;32:360-367.  https://doi.org/10.1016/j.annonc.2020.11.004
  42. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 2010;6:278-285.  https://doi.org/10.1111/j.1743-7563.2010.01331.x
  43. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012;84:e585-e592.  https://doi.org/10.1016/j.ijrobp.2012.07.2378
  44. Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012;104:361-366. https://doi.org/10.1016/j.radonc.2012.08.024
  45. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130-3136.  https://doi.org/10.1200/JCO.2014.58.3930
  46. van Amelsfoort RM, Walraven I, Kieffer J, Jansen EPM, Cats A, van Grieken NCT, et al. Quality of life is associated with survival in patients with gastric cancer: results from the randomized CRITICS trial. J Natl Compr Canc Netw 2022;20:261-267.  https://doi.org/10.6004/jnccn.2021.7057
  47. Kim TH, Kim IH, Kang SJ, Choi M, Kim BH, Eom BW, et al. Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer 2023;23:3-106.  https://doi.org/10.5230/jgc.2023.23.e11
  48. Yu JI, Choi C, Lee J, Kang WK, Park SH, Kim ST, et al. Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: analysis of the ARTIST phase III trial. Radiother Oncol 2020;152:19-25.  https://doi.org/10.1016/j.radonc.2020.07.043
  49. Yu JI, Park HC, Lee J, Choi C, Kang WK, Park SH, et al. Outcomes of radiotherapy for mesenchymal and non-mesenchymal subtypes of gastric cancer. Cancers (Basel) 2020;12:943. 
  50. Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, et al. Clinical outcomes and the role of adjuvant concurrent chemoradiation therapy in D2-resected LN-positive young patients (≤45 years) with gastric cancer. Anticancer Res 2019;39:5811-5820.  https://doi.org/10.21873/anticanres.13785
  51. Park JS, Yu JI, Lim DH, Nam H, Kim YI, Lee J, et al. Clinical significance of preoperative hematological parameters in patients with D2-resected, node-positive stomach cancer. Biomedicines 2022;10:1565. 
  52. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456.  https://doi.org/10.1038/nm.3850
  53. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. https://doi.org/10.1038/nature13480
  54. Kim ST, Sa JK, Oh SY, Kim K, Hong JY, Kang WK, et al. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Med 2021;13:11.
  55. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 2018;9:1777. 
  56. Lee J, An JY, Choi MG, Park SH, Kim ST, Lee JH, et al. Deep learning-based survival analysis identified associations between molecular subtype and optimal adjuvant treatment of patients with gastric cancer. JCO Clin Cancer Inform 2018;2:1-14. https://doi.org/10.1200/CCI.17.00065